Preclinical and clinical activity of the topoisomerase i inhibitor, karenitecin, in melanoma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 11, 2011, Pages 1565-1574

  Munster, Pamela N ^a   Daud, Adil I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Camptothecins; Karenitecin (cositecan); Melanoma; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; COSITECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; TOPOTECAN; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG DESIGN; ENZYME INHIBITION; GENE MUTATION; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; REVIEW;

ANIMALS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOPOISOMERASE I INHIBITORS;

EID: 80053983398     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.617740     Document Type: Review

References (30)

1. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8(3):641-61 (Pubitemid 34742090)
2. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17(5):421-33
3. Sieber SM, Mead JA, Adamson RH. Pharmacology of antitumor agents from higher plants. Cancer Treat Rep 1976;20(8):1127-39
4. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972;56(4):515-21
5. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008;75(6):1262-71 (Pubitemid 351305209)
6. Van Hattum AH, Pinedo HM, Schluper HM, et al. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000;88(2):260-6
7. Boven E, Van Hattum AH, Hoogsteen I, et al. New analogues of camptothecins. Activity and resistance. Ann NY Acad Sci 2000;922:175-7 (Pubitemid 32050251)
8. Yao S, Murali D, Seetharamulu P, et al. Topotecan lactone selectively binds to double-and single-stranded DNA in the absence of topoisomerase I. Cancer Res 1998;58(17):3782-6 (Pubitemid 28405630)
9. Van Hattum AH, Schluper HMM, Hausheer FH, et al. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int J Cancer 2002;100(1):22-9 (Pubitemid 34602060)
10. Maliepaard M, van Gastelen MA, Tohgo A, et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 2001;7(4):935-41 (Pubitemid 32708732)
11. Thompson PA, Berg SL, Aleksic A, et al. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol 2004;53(6):527-32 (Pubitemid 38680251)
12. Keir ST, Hausheer F, Lawless AA, et al. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother Pharmacol 2001;48(1):83-7 (Pubitemid 32662441)
13. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008;5(6):e120
14. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54 (Pubitemid 34716871)
15. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [Internet]. N Engl J Med 2011;Available from: http://www.ncbi. nlm.nih.gov/pubmed/21639808 [[Cited 26 June 2011]
16. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467(7315):596-9
17. Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci 2006;11:1-14 (Pubitemid 43253470)
18. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69(2):609-15
19. Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov 2008;3(2):105-13
20. Tarhini AA, Kirkwood JM. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 2008;8(10):1583-93
21. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
22. Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010;2:197-211
23. Phase I Trial of Karenitecin (KT) Administered Intravenously Daily for Five Consecutive Days in Patients with Advanced Solid Tumors Using Accelerated Dose Titration.-ASCO [Internet]. [date unknown];[cited 15:50:21] Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst-detail- view& confID=2&abstractID=200862
24. Phase I Trial of Karenitecin (KT) Administered Intravenously Daily for Five Consecutive Days in Patients with Advanced Solid Tumors Using Accelerated Dose Titration.-ASCO [Internet]. [date unknown];[cited 15:50:22] Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?& vmview=abst-detail- view&confID=2& abstractID=200862
25. Daud A, Valkov N, Centeno B, et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 2005;11(8):3009-16 (Pubitemid 40525206)
26. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25(15):1979-85 (Pubitemid 46972780)
27. Grossman SA, Carson KA, Phuphanich S, et al. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neurooncol 2008;10(4):608-16
28. Daud AI, Dawson J, DeConti RC, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 2009;15(7):2479-87
29. Kavanagh JJ, Sill MW, Ramirez PT, et al. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2008;18(3):460-4 (Pubitemid 351668320)
30. Miller AA, Herndon JE, Gu L, Green MR. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer 2005;48(3):399-407 (Pubitemid 40693626)